Infen-25 Use In Pregnancy & Lactation

Dexketoprofen tablets are contraindicated during third trimester of pregnancy and lactation. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. Nevertheless, animal studies with dexketoprofen trometamol haven't shown reproductive toxicity During the first and second trimester of pregnancy, dexketoprofen trometamol should not be given unless clearly necessary. If dexketoprofen trometamol is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to the risk of premature closure of the ductus arteriosus, pulmonary hypertension, renal dysfunction, prolongation of bleeding time, an anti-aggregating, delayed or prolonged labour. It is not known whether dexketoprofen is excreted in human milk.